A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy

Darrell WuDunn, Louis Cantor, Angelita M. Palanca-Capistrano, Joni Hoop, Nishat P. Alvi, Charles Finley, Vipul Lakhani, Alan Burnstein, Stephenie L. Knotts

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

PURPOSE: To compare the safety and efficacy of intraoperative 5-fluorouracil (5-FU) or Intraoperative mitomycin C (MMC) in eyes undergoing primary trabeculectomy. DESIGN: Prospective double-masked randomized clinical trial. METHODS: One hundred fifteen eyes of 103 patients with uncontrolled intraocular pressure (IOP) despite maximally tolerated medical therapy or laser were prospectively randomized in a double-masked fashion to one of two treatment groups in a single institution setting. Subject's eyes underwent primary trabeculectomy with either topical 5-FU (50 mg/ml for 5 minutes) or topical MMC (0.2 mg/ml for 2 minutes). Primary outcome measures included the number of eyes achieving target pressures of 21, 18, 15, and 12 mm Hg at 6 and 12 months postoperatively. Secondary outcome measures included IOP, best-corrected visual acuity, complications, and interventions. RESULTS: Of the 115 eyes, 57 received 5-FU while 58 received MMC. A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00). At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P = .49). The most common complications in each group were persistent choroidal effusions and bleb leak. CONCLUSION: Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.

Original languageEnglish
Pages (from-to)521-528
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume134
Issue number4
DOIs
StatePublished - Oct 1 2002

Fingerprint

Trabeculectomy
Mitomycin
Fluorouracil
Intraocular Pressure
Outcome Assessment (Health Care)
Laser Therapy
Blister
Visual Acuity
Randomized Controlled Trials
Safety
Pressure

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. / WuDunn, Darrell; Cantor, Louis; Palanca-Capistrano, Angelita M.; Hoop, Joni; Alvi, Nishat P.; Finley, Charles; Lakhani, Vipul; Burnstein, Alan; Knotts, Stephenie L.

In: American Journal of Ophthalmology, Vol. 134, No. 4, 01.10.2002, p. 521-528.

Research output: Contribution to journalArticle

WuDunn, D, Cantor, L, Palanca-Capistrano, AM, Hoop, J, Alvi, NP, Finley, C, Lakhani, V, Burnstein, A & Knotts, SL 2002, 'A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy', American Journal of Ophthalmology, vol. 134, no. 4, pp. 521-528. https://doi.org/10.1016/S0002-9394(02)01627-6
WuDunn, Darrell ; Cantor, Louis ; Palanca-Capistrano, Angelita M. ; Hoop, Joni ; Alvi, Nishat P. ; Finley, Charles ; Lakhani, Vipul ; Burnstein, Alan ; Knotts, Stephenie L. / A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. In: American Journal of Ophthalmology. 2002 ; Vol. 134, No. 4. pp. 521-528.
@article{ab260b25663244198e93c7e60c5db285,
title = "A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy",
abstract = "PURPOSE: To compare the safety and efficacy of intraoperative 5-fluorouracil (5-FU) or Intraoperative mitomycin C (MMC) in eyes undergoing primary trabeculectomy. DESIGN: Prospective double-masked randomized clinical trial. METHODS: One hundred fifteen eyes of 103 patients with uncontrolled intraocular pressure (IOP) despite maximally tolerated medical therapy or laser were prospectively randomized in a double-masked fashion to one of two treatment groups in a single institution setting. Subject's eyes underwent primary trabeculectomy with either topical 5-FU (50 mg/ml for 5 minutes) or topical MMC (0.2 mg/ml for 2 minutes). Primary outcome measures included the number of eyes achieving target pressures of 21, 18, 15, and 12 mm Hg at 6 and 12 months postoperatively. Secondary outcome measures included IOP, best-corrected visual acuity, complications, and interventions. RESULTS: Of the 115 eyes, 57 received 5-FU while 58 received MMC. A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95{\%}) eyes in the 5-FU group and 54 of 57 (95{\%}) eyes in the MMC group (P = 1.00). At 12 months, 45 of 48 (94{\%}) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89{\%}) eyes in the MMC group did (P = .49). The most common complications in each group were persistent choroidal effusions and bleb leak. CONCLUSION: Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.",
author = "Darrell WuDunn and Louis Cantor and Palanca-Capistrano, {Angelita M.} and Joni Hoop and Alvi, {Nishat P.} and Charles Finley and Vipul Lakhani and Alan Burnstein and Knotts, {Stephenie L.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1016/S0002-9394(02)01627-6",
language = "English",
volume = "134",
pages = "521--528",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy

AU - WuDunn, Darrell

AU - Cantor, Louis

AU - Palanca-Capistrano, Angelita M.

AU - Hoop, Joni

AU - Alvi, Nishat P.

AU - Finley, Charles

AU - Lakhani, Vipul

AU - Burnstein, Alan

AU - Knotts, Stephenie L.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - PURPOSE: To compare the safety and efficacy of intraoperative 5-fluorouracil (5-FU) or Intraoperative mitomycin C (MMC) in eyes undergoing primary trabeculectomy. DESIGN: Prospective double-masked randomized clinical trial. METHODS: One hundred fifteen eyes of 103 patients with uncontrolled intraocular pressure (IOP) despite maximally tolerated medical therapy or laser were prospectively randomized in a double-masked fashion to one of two treatment groups in a single institution setting. Subject's eyes underwent primary trabeculectomy with either topical 5-FU (50 mg/ml for 5 minutes) or topical MMC (0.2 mg/ml for 2 minutes). Primary outcome measures included the number of eyes achieving target pressures of 21, 18, 15, and 12 mm Hg at 6 and 12 months postoperatively. Secondary outcome measures included IOP, best-corrected visual acuity, complications, and interventions. RESULTS: Of the 115 eyes, 57 received 5-FU while 58 received MMC. A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00). At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P = .49). The most common complications in each group were persistent choroidal effusions and bleb leak. CONCLUSION: Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.

AB - PURPOSE: To compare the safety and efficacy of intraoperative 5-fluorouracil (5-FU) or Intraoperative mitomycin C (MMC) in eyes undergoing primary trabeculectomy. DESIGN: Prospective double-masked randomized clinical trial. METHODS: One hundred fifteen eyes of 103 patients with uncontrolled intraocular pressure (IOP) despite maximally tolerated medical therapy or laser were prospectively randomized in a double-masked fashion to one of two treatment groups in a single institution setting. Subject's eyes underwent primary trabeculectomy with either topical 5-FU (50 mg/ml for 5 minutes) or topical MMC (0.2 mg/ml for 2 minutes). Primary outcome measures included the number of eyes achieving target pressures of 21, 18, 15, and 12 mm Hg at 6 and 12 months postoperatively. Secondary outcome measures included IOP, best-corrected visual acuity, complications, and interventions. RESULTS: Of the 115 eyes, 57 received 5-FU while 58 received MMC. A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00). At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P = .49). The most common complications in each group were persistent choroidal effusions and bleb leak. CONCLUSION: Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.

UR - http://www.scopus.com/inward/record.url?scp=0036808054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036808054&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(02)01627-6

DO - 10.1016/S0002-9394(02)01627-6

M3 - Article

C2 - 12383808

AN - SCOPUS:0036808054

VL - 134

SP - 521

EP - 528

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -